International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols-Reference-Cited by-同舟云学术

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols

Published:2010-10-13 Issue:5 Volume:117 Page:1001-1009
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Waheed Sarah,Shaughnessy John D.,van Rhee Frits,Alsayed Yazan,Nair Bijay,Anaissie Elias,Szymonifka Jackie,Hoering Antje,Crowley John,Barlogie Bart

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25535/fullpdf

Reference16 articles.

1. Thalidomide and hematopoietic-cell transplantation for multiple myeloma;Barlogie;N Engl J Med.,2006

2. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3;Barlogie;Br J Haematol.,2007

3. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1;Shaughnessy;Blood.,2007

4. International staging system for multiple myeloma;Greipp;J Clin Oncol.,2005

5. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2;Pineda-Roman;Br J Haematol.,2008

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma Cell Dyscrasias;Tata Memorial Centre Textbook of Oncology;2024

2. Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma;Haematologica;2022-09-29

3. Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics;British Journal of Haematology;2021-05-25

4. Conventional Cytogenetic Abnormalities in Plasma Cell Myeloma and Their Prognostic Effect: A Single Center Experience in the Middle East;MIDDLE EAST J CANCER;2021

5. Targeting BCL ‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma;American Journal of Hematology;2021-01-19